FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPR	OVAL
OMB Number:	3235-0287
Estimated average	burden
nours per response	0.5

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Typ	e Responses)													
1. Name and Address of Reporting Person *- LANDRY DONALD W			Tonix Pharmaceuticals Holding Corp. [TNXP] 3. Date of Earliest Transaction (Month/Day/Year) 02/09/2016					P1	S. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_Director						
(Last) (First) (Middle) C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., STE 306								w)							
(Street) NEW YORK, NY 10022													ine)		
(City)		(State)	(Zip)		1	Гable I	[- No	n-Derivati	ve Securiti	es Acquire	d, Dispose	d of, or Be	neficially Ow	ned	
1.Title of Security (Instr. 3)					ate, i	if Cod (Inst	ode		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		eneficially eported Tra	Owned Foll insaction(s)	I	Ownership Form:	Beneficial
				(Month/Day	/Yeaı		ode	V Am	(A) o	((Instr. 3 and 4) Direct (D) Own or Indirect (I) (Instr. 4)		Ownership Instr. 4)		
													ond unless	the	
								form disp	olays a cu	rrently va	ilid OMB	ed to respo control nu		the	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Ye	3A. Deemed Execution Date	Code	tion S	varran 5. Num of Derivat Securit Acquire (A) or Dispose	ts, or ber ive ies ed	form disposed, Dispose	ed of, or Be vertible sec ercisable ion Date	rrently va	Owned of ng	8. Price of	9. Number o Derivative Securities Beneficially Owned Following Reported	f 10. Ownersh Form of Derivativ Security: Direct (D or Indirec	
Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date	e.g., puts, ca 4. Transact Code	tion () () () () () () () () () () () () ()	varran 5. Num of Derivat Securit Acquire (A) or	ts, or ber ive ies ed	ed, Dispose otions, conv 6. Date Exe and Expirat	ed of, or Be vertible sec ercisable ion Date	rrently valuation of the control of	Owned of ng	8. Price of Derivative Security	9. Number o Derivative Securities Beneficially Owned Following	f 10. Ownersh Form of Derivativ Security: Direct (D or Indirec	p of Indirect Beneficial Ownershi (Instr. 4)
Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date	e.g., puts, ca 4. Transact Code	tion (I)	varran 5. Num of Derivat Securiti Acquire (A) or Dispose of (D) (Instr. 3 and 5)	ts, or ber sive sies ed ed	ed, Dispose otions, conv 6. Date Exe and Expirat	ed of, or Be ertible sec rerisable ion Date y/Year)	rrently varies) 7. Title an Amount of Underlying Securities (Instr. 3 a	Owned of ng	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(f 10. Ownersh Form of Derivativ Security: Direct (D or Indirects)	p of Indirect Beneficia Ownersh (Instr. 4)

	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
LANDRY DONALD W C/O TONIX PHARMACEUTICALS HOLDING CORP 509 MADISON AVE., STE 306 NEW YORK, NY 10022	X				

Signatures

/s/Jessica Morris, Attorney-in-Fact	02/10/2016
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Each restricted stock unit represents the right to receive, at settlement, one share of common stock.
- (2) These restricted stock units are scheduled to vest 100% on February 9, 2017.
- (3) The restricted stock units were granted pursuant to the Issuer's 2014 Stock Incentive Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.